Products
B2B Zone
6th RNAi-Based Therapeutics Summit
6th RNAi-Based Therapeutics Summit
Conferences

6th RNAi-Based Therapeutics Summit

By

Hanson Wade

2 Followers
28 Jan 2025 - 30 Jan 2025
Free Registration

Event Details

6th RNAi-Based Therapeutics Summit

As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi therapeutics to treat a plethora of diseases grows. Now more than ever, RNAi therapies hold promise to treat diseases beyond the liver and provide efficacious, tolerable treatment options for patients.

The 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies, data from clinically successful extra-hepatic targeting, cutting-edge AI tools to assist payload design, and breakthrough chemical modifications which enhance stability, allowing for precise therapeutic delivery.

Uniting 70+ leaders of the RNAi world, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk, Alynlam, Switch Therapeutics, Aro Biotherapeutics, Novartis, Comanche Biopharma and more, this meeting is a unique gathering of RNAi's sharpest minds, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need.


URLs:
Website: https://go.evvnt.com/2676365-0?pid=10018
Tickets: https://go.evvnt.com/2676365-2?pid=10018
Brochure: https://go.evvnt.com/2676365-3?pid=10018

Prices:
Conference + Workshop Day - Drug Developer Pricing: USD 4197.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Workshop Day - Academic Pricing: USD 3597.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + Workshop Day - Solution Provider Pricing: USD 5097.00,
Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Adam Dinerman, Senior Vice President and Head of Chemistry, Manufacturing and Controls, Aro Biotherapeutics , Ali Shah, Co-Founder and Chief Executive Officer, Tallas Biotech, Andrew Fraley, Partner, Sunrise Bioventures, Ashling Holland, Director of Research and Preclinical Development, PepGen, Benjamin Kreitman, Principal, Broadview Ventures, Chad Miller, Head of Research, Nosis Biosciences, David Jackson, Chief Executive Officer, Ceria Therapeutics, David Sharp, Chief Executive Officer, Microcures, Eriks Rozners, Professor, Binghamton University Research Foundation, Glenn Kazo, Chief Business Officer, ARIZ Precision Medicines, Hanhua Huang, Vice President, Biology, Avidity Biosciences, Hunghao Chu, Associate Director, Benitec Ltd, Jingfang Ju, Professor, Stony Brook University, Julia Alterman, Assistant Professor, University of Massachusetts Medical School, Lucas Siow, Chief Executive Officer and Co-Founder, ProteinQure, Mohammad Shadid, Vice President - Preclinical Development, Korro Bio, Ruben Postel, Chief Scientific Officer and Scientific Founder, Sapreme Technologies, Scott Harper, Co-founder, Armatus Bio and Principal Investigator, Nationwide Children's Hospital, Shanthi Ganesh, Director - Global Nucleic Acid Therapies, Novo Nordisk, Shilpi Mahajan, Associate Director and Head of Bioanalytics, Switch Therapeutics, Vignesh Narayan Hariharan, Director of Biology, Comanche Biopharma and Instructor, University of Massachusetts Medical School, Weimin Wang, Founder and Chief Executive Officer, SanegeneBio, Yuanyuan Jin, Co-founder and Chief Operating Officer, Bound Therapeutics, Zdravka Medarova, Chief Scientific Officer, TransCode Therapeutics, Zhanna Druzina, Senior Director, Aro Biotherapeutics, Zhihong Huang, Associate Director, Global Discovery Chemistry, Novartis AG

Entry Fees

Free Registration

Categories

Event Frequency

One Time

Event Timings

(GMT-5:00) Central Time (US and Canada)
08:00 AM - 06:00 PM (Jan 28, Jan 29, Jan 30) (Public)

Speakers

Adam Dinerman
Adam Dinerman
Senior Vice President and Head of Chemistry, Manufacturing and Controls, Aro Biotherapeutics
Ali Shah
Ali Shah
Co-Founder and Chief Executive Officer, Tallas Biotech
Andrew Fraley
Andrew Fraley
Partner, Sunrise Bioventures
Ashling Holland
Ashling Holland
Director of Research and Preclinical Development, PepGen

Comments on 6th RNAi-Based Therapeutics Summit

You must to write a comment.

Peoples Interested in Visit

0 Peoples Interested to Visit

Event Location

W Boston
100 Stuart Street ,
Boston 02116, Massachusetts, United States
Official Link :

More Events By Organizer

2nd Covalent Drug Discovery and Development Summit
2nd Covalent Drug Discovery and Development Summit
10
Dec
2024
Free
Conferences
Personalized Cancer Vaccine Summit
Personalized Cancer Vaccine Summit
03
Dec
2024
Free
Conferences
Cell and Gene Therapy Medical Affairs Summit
Cell and Gene Therapy Medical Affairs Summit
03
Dec
2024
Free
Conferences
Patient Recruitment for Rare Disease Trials Summit 2024
Patient Recruitment for Rare Disease Trials Summit 2024
10
Dec
2024
Free
Conferences
GPCRs-Targeted Drug Discovery Summit Europe
GPCRs-Targeted Drug Discovery Summit Europe
26
Nov
2024

GPCRs-Targeted Drug Discovery Summit Europe

Greater London, United Kingdom
Free
Conferences
Portfolio Strategy and Decision Making for Biopharma Summit 2024
Portfolio Strategy and Decision Making for Biopharma Summit 2024
21
Nov
2024

Similar Events

Pharmacy Career Conference 2021
Pharmacy Career Conference 2021
24
Oct
2022
Free
Conferences
Pharma IT Summit & Awards
Pharma IT Summit & Awards
07
Dec
2022
Free
Conferences
Asia Bio Partnering Forum
Asia Bio Partnering Forum
24
Apr
2024
Free
Conferences
Oligonucleotides CMC and Analytical Development Summit
Oligonucleotides CMC and Analytical Development Summit
29
Aug
2023
Free
Conferences
Benefits of Signin
  • Publish Your Event for Free
  • Find Upcoming Events Near By
  • Grow Your B2B Network
  • Fix B2B Meeting Online/Event
  • Showcase Products to Right People